ALVO
Alvotech Ordinary Shares
Biological Products, (No Diagnostic Substances)
Best Pharmaceutical Stocks 2026 →
Alvotech Ordinary Shares (ALVO) Stock: Buy, Sell, or Hold?
$4.92
+0.04 (+0.82%)
▲
5d:
+5.35%
30d:
-8.55%
90d:
+20.29%
QUANTITATIVE VERDICT
BUY
MODERATE Confidence (94%)
Quality Score
65/100
Position
SLIGHTLY LOW
30-Day Fair Range
$4.64 – $5.60
Position: SLIGHTLY LOW
Forward P/E & Valuation
21.6x
STRETCHED
vs 17.4x historical avg
Wall Street Target
$7.20
+46.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$4.47 / $5.03
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
💡 BUY OPPORTUNITY: ALVO shows positive signals but monitor for confirmation. Market pricing in 7.4% growth. Moderate conviction.
Get Alerted When ALVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.56
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.45
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALVO is currently trading at $4.92, which is considered slightly low relative to its 30-day fair value range of $4.64 to $5.60. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.6) compared to its historical average (17.4). At these levels, the market is pricing in 7.4% annual earnings growth.
Technical Outlook: Technically, ALVO is in a strong uptrend. The price is approaching resistance at $5.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ALVO scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.20 (+46.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALVO is in a strong uptrend. The price is approaching resistance at $5.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ALVO scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.20 (+46.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.64 -
$5.60
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
93.8%
Trading Range & Key Levels
30-Day Trading Range
$4.64 -
$5.60
Current vs Trading Range
SLIGHTLY LOW
Support Level
$4.47
Resistance Level
$5.03
Current Trend
Strong Uptrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 46.3% below Wall St target ($7.20)
- BULLISH: Expecting earnings turnaround to 7.4% growth with -38.9% revenue growth
- BULLISH: Bottoming setup score 69/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
21.57
Wall Street Target
$7.20
(+46.3%)
Revenue Growth (YoY)
-38.9%
Earnings Growth (YoY)
-99.0%
Profit Margin
-36.3%
Valuation Premium vs History
+7.4% premium
PE vs Historical
21.6 vs 17.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.4%
(market-implied from PE analysis)
1-Year Target
$5.28
(+7%)
2-Year Target
$5.68
(+15%)
3-Year Target
$6.10
(+24%)
3-Yr Target (if PE normalizes)
(PE: 22→17)
PE COMPRESSION
$4.92
(0%)
Earnings growth offset by PE compression
Share ALVO Analysis
Share this live ALVO analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ALVO)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 5, 2026
Daily AI digest
AI Retail Discussion Summary:
Vericel Corporation (VCEL) reported Q3 earnings and revenues that surpassed estimates, leading to an earnings surprise of 1,250.00% and a revenue surprise of 9.03%. The company has beaten consensus estimates for both earnings and revenues in the last four quarters.
Key Retail Themes:
Positive earnings report
Strong financial performance
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:29 AM ET
Data refreshes hourly during market hours. Next update: 3:29 AM
Data refreshes hourly during market hours. Next update: 3:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ALVO Research Pages
